Blue Earth Diagnostics Highlights Upcoming Presentation of Key Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the upcoming oral presentation of key results from its Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer, at the upcoming ASCO 2022 Genitourinary Cancers Symposium (ASCO GU). The conference will be held in-person in San Francisco, Calif, and online from February 17 to 19, 2022.18F-rhPSMA-7.3 is an investigational Prostate-Specific Membrane Antigen-targeted radiohybrid (rh) PET imaging agent. The SPOTLIGHT study (NCT04186845) is a Phase 3, multi-center, single-arm imaging study, conducted in the United States and Europe, to evaluate the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy.

Details of the presentation are listed below.

Highlighted 18F-rhPSMA-7.3 Oral Presentation

• Date: Thursday, February 17, 2022
• Track: Prostate Cancer
• Title: Detection Rates of 18F-rhPSMA-7.3 PET in Patients with Suspected Prostate Cancer
• Recurrence: Results from a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)
• Presenter: David M. Schuster, MD, FACR, Winship Cancer Institute of Emory University, Atlanta, Ga.
• Session: General Session - Evolution of Multidisciplinary Management Across the Spectrum of
• Prostate Cancer Abstract: 9
• Location: In-person and online/Level 3, ballroom
• Session Time: 6:00 PM ET- 7:30 PM ET (3:00 PM PT - 4:30 PM PT) Presentation: 7:00 PM ET (4:00 PM PT)

Blue Earth Diagnostics invites participants at the ASCO 2022 Genitourinary Cancers Symposium to attend the presentation above. Participants on-site are also invited to visit Blue Earth Diagnostics` Medical Affairs booth (#50). For full session details and scientific presentation listings, please see the ASCO GU online program here.